Juno Therapeutics Reports Third Quarter 2017 Financial Results
JUNO THERAPEUTICS (JUNO)
Last juno therapeutics earnings: 11/1 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.junotherapeutics.com/investor-relations
Company Research
Source: Business Wire
- TRANSCEND pivotal trial ongoing using dose level 2 - - Promising data with JCAR017 in DLBCL at dose level 2: 80% (12/15) ORR and 73% (11/15) CR rate at 3 months in core group - - 1% (1/69) severe CRS and 14% (10/69) severe NT rates in full group: safety profile appears similar across doses as well as the full and core groups - - 15 abstracts to be presented at upcoming ASH Conference - - Product candidates in clinical trials against eight different targets - - Strong cash position of $1.06 billion - - 2017 cash burn expected to be in the lower half of guidance range - - Conference call today at 4:30 p.m. Eastern Time - SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights
Show less
Read more
Impact Snapshot
Event Time:
JUNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JUNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JUNO alerts
High impacting JUNO THERAPEUTICS news events
Weekly update
A roundup of the hottest topics